Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.62 |
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.61 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17984422 | 1.00 | KDM1A (0.62) | KDM1AP2RY12ADAMTS4ADAMTS5 | |
| SCHEMBL18016076 | 0.91 | KDM1A (0.62) | KDM1AP2RY12 | |
| SCHEMBL16447224 | 0.89 | KDM1A (0.62) | KDM1AP2RY12 | |
| SCHEMBL18043513 | 0.89 | KDM1A (0.62) | KDM1AP2RY12 | |
| SCHEMBL17984482 | 0.88 | KDM1A (0.64) | KDM1AP2RY12 | |
| SCHEMBL16447401 | 0.88 | KDM1A (0.56) | KDM1AP2RY12 | |
| SCHEMBL18043515 | 0.88 | KDM1A (0.56) | KDM1AP2RY12 | |
| SCHEMBL18848617 | 0.87 | KDM1A (0.63) | KDM1AP2RY12 | |
| SCHEMBL16455183 | 0.86 | KDM1A (0.64) | KDM1AP2RY12 | |
| SCHEMBL16455173 | 0.86 | KDM1A (0.67) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885P2RY12 4813/4885ADAMTS4 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.